Slide 1: Conference Call Preliminary Full-Year 2018 Results
Conference Call Preliminary Full-Year 2018 Results Joachim Kreuzburg (CEO), Rainer Lehmann (CFO) January 29, 2019
Slide 2: Disclaimer
Disclaimer This presentation contains statements concerning the future performance of the Sartorius Group and the Sartorius Stedim Biotech Group. These statements are based on assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we cannot guarante
Slide 3: Agenda
Agenda Sartorius Group FY 2018 Results | FY 2019 Guidance Sartorius Stedim Biotech Group FY 2018 Results | FY 2019 Guidance Questions & Answers
Slide 4: FY 2018 Highlights
FY 2018 Highlights Double-digit growth in sales, order intake and earnings Dynamic profitable growth in Bioprocess Solutions; strong order intake Lab Products & Services with robust development in weakening economy Optimistic outlook for 2019 4
Slide 5: Strong top-line growth; further margin increase
Strong top-line growth; further margin increase Sartorius Group in millions of € unless otherwise specified FY 2017 FY 2018 in % in % cc 1) Sales revenue 1,404.6 1,566.0 +11.5 +13.2 Order intake 1,501.4 1,662.5 +10.7 +12.5 Underlying EBITDA2) 353.2 405.0 +14.7 Underlying EBITDA2) margin in % 25.1 25
Slide 6: Growth in all regions; the Americas record strongest gains
Growth in all regions; the Americas record strongest gains Americas EMEA Asia|Pacific Sales by Region € in millions € in millions € in millions in % 657.7 EMEA ~ 42% 604.5 520.1 455.5 388.2 Americas ~ 33% 344.6 €1,566.0m Asia|Pacific ~ 25% FY 17 FY 18 FY 17 FY 18 FY 17 FY 18 +16.6 % +9.4 % +15.5 % A
Slide 7: BPS: Very dynamic development; yet against moderate comps
BPS: Very dynamic development; yet against moderate comps Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +14.9% cc +14.8% cc +15.7% +13.0% +13.1% 1,233.7 326.9 1,143.1 1,091.3 282.4 1,010.3 28.6% 28.0% FY 17 FY 18 FY 17 FY 18 FY 17 FY 18 Continuing
Slide 8: LPS: Solid performance, yet macro uncertainties weigh on growth
LPS: Solid performance, yet macro uncertainties weigh on growth Order Intake Sales Revenue Underlying EBITDA & Margin € in millions € in millions € in millions +6.3% cc +9.1% cc +10.4% +4.6% +7.3% 428.8 423.0 410.1 78.1 394.2 70.8 18.0% 18.5% FY 17 FY 18 FY 17 FY 18 FY 17 FY 18 Sales and order gro
Slide 9: Cash flow enhanced by higher earnings
Cash flow enhanced by higher earnings Sartorius Group € in millions unless otherwise specified FY 20171) FY 2018 in % Net operating cash flow driven by higher earnings Underlying EBITDA 353.2 405.0 +14.7 Positive effect on extraordinary Extraordinary items -35.5 -1.7 +95.3 items due to cancellat
Slide 10: Key financial indicators remain at robust levels
Key financial indicators remain at robust levels Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Group Dec. 31, 2017 Dec. 31, 2018 1000 3.0 Equity ratio in % 35.1 38.5 800 2.4 600 1.8 Net debt in millions of € 895.5 959.5 400 1.2 Net debt | underlying EBITDA 2.5 2.4 200
Slide 11: Outlook for 2019
Outlook for 2019 FY 2018 FY 2019 Guidance1) Sales Revenue Underlying Sales Revenue Underlying Growth1) EBITDA Margin Growth EBITDA Margin slightly above Sartorius Group 13.2% 25.9% ~ 7% - 11% 27.0% slightly above Bioprocess Solutions 14.8% 28.6% ~ 8% - 12% 29.5% slightly above Lab Products & Service
Slide 12: Agenda
Agenda Sartorius Group FY 2018 Results | FY 2019 Guidance Sartorius Stedim Biotech Group FY 2018 Results | FY 2019 Guidance Questions & Answers
Slide 13: Very dynamic profitable growth against moderate comps
Very dynamic profitable growth against moderate comps Sartorius Stedim Biotech Group in millions of € unless otherwise specified FY 2017 FY 2018 in % in % cc 1) Sales revenue 1,081.0 1,212.2 +12.1 +13.7 Order intake 1,162.3 1,307.3 +12.5 +14.2 Underlying EBITDA2) 294.9 342.4 +16.1 Underlying EBITDA2
Slide 14: Growth in all regions, the Americas with highest momentum
Growth in all regions, the Americas with highest momentum Americas EMEA Asia|Pacific Sales by Regions in € millions in € millions in € millions in % 508.2 460.7 422.6 368.8 EMEA ~ 42% 281.3 251.6 Americas ~ 35% €1,212.2m FY 17 FY 18 FY 17 FY 18 FY 17 FY 18 +16.9% +10.7% +14.7% Asia|Pacific ~ 23% Acc
Slide 15: Significant increase in operating cash flow
Significant increase in operating cash flow Sartorius Stedim Biotech Group € in millions unless otherwise specified FY 2017 FY 2018 in % Net operating cash flow driven by higher earnings Underlying EBITDA 294.9 342.4 +16.1 Positive effect on extraordinary Extraordinary items -22.6 +12.7 +156.4 i
Slide 16: Financial position remains strong
Financial position remains strong Key Financial Indicators Net Debt and Net Debt to Underlying EBITDA Sartorius Stedim Biotech Dec. 31, 2017 Dec. 31, 2018 180 1.8 Equity ratio in % 62.6 66.5 150 1.5 120 1.2 Net debt in millions of € 127.1 125.7 90 0.9 60 0.6 Net debt | underlying EBITDA 0.4 0.4 30 0
Slide 17: Outlook for 2019
Outlook for 2019 FY 2018 FY 20191) Sales revenue growth 13.7%1) ~ 7% - 11% slightly more than Underlying EBITDA margin 28.2% + 1pp CAPEX ratio 14.6% ~ 11% 1) In constant currencies Sales guidance includes dilution of 3pp sales growth due to the modification of the cell culture media agreement with
Slide 18: = sartorius
= sartorius OQaA
Slide 19: Thank you very much for your attention
Thank you very much for your attention